Perioperative and oncological outcomes following minimally invasive versus open pancreaticoduodenectomy for pancreatic duct adenocarcinoma

• Published in: Surgical endoscopy Vol. 35; no. 5; pp. 2273 - 2285
• Main Authors: Sun, Rui, Yu, Jiawen, Zhang, Yifan, Liang, Zhika, Han, Xianlin
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.05.2021; Springer Nature B.V
• Subjects: Abdominal Surgery; Chemotherapy; Endoscopy; Gastroenterology; Gynecology; Hepatology; Hospitals; Investigations; Laparoscopy; Length of stay; Lymphatic system; Medicine; Medicine & Public Health; Meta-analysis; Morbidity; Mortality; Pancreatic cancer; Pancreaticoduodenectomy; Pediatrics; Proctology; Robotics; Surgery; Veins & arteries; Pancreatic ductal carcinoma; Laparoscopic surgery; Minimally invasive surgery; Pancreaticoduodenectomy; Robotic surgical procedures; Meta-analysis
• DOI: 10.1007/s00464-020-07641-1
• ISSN: 0930-2794

Background The outcomes of minimally invasive pancreaticoduodenectomy have not been adequately compared with those of open pancreaticoduodenectomy in patients with pancreatic ductal adenocarcinoma. We performed a meta‐analysis to compare the perioperative and oncological outcomes of these two pancreaticoduodenectomy procedures specifically in patients with pancreatic ductal adenocarcinoma. Methods Before this study was initiated, a specific protocol was designed and has been registered in PROSEPRO (ID: CRD42020149438). Using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, PubMed, EMBASE, Web of Science, Cochrane Central Register, and ClinicalTrials.gov databases were systematically searched for studies published between January 1994 and October 2019. Overall survival, disease-free survival, and time to commencing adjuvant chemotherapy were the primary endpoint measurements, whereas perioperative and short-term outcomes were the secondary endpoints. Results The final analysis included 9 retrospective cohorts comprising 11,242 patients (1377 who underwent minimally invasive pancreaticoduodenectomy and 9865 who underwent open pancreaticoduodenectomy). There were no significant differences in the patients’ overall survival, operative time, postoperative complications, 30-day mortality, rate of vein resection, number of harvested lymph nodes, or rate of positive lymph nodes between the two approaches. However, disease-free survival, time to starting adjuvant chemotherapy, length of hospital stay, and rate of negative margins in patients who underwent minimally invasive pancreaticoduodenectomy showed improvements relative to those in patients who underwent open surgery. Conclusions Minimally invasive pancreaticoduodenectomy provides similar or even improved perioperative, short-term, and long-term oncological outcomes when compared with open pancreaticoduodenectomy for patients with pancreatic ductal adenocarcinoma.